SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Franklin D. Roosevelt Synthetic CCD

PatientFranklin D. Roosevelt
Date of birth1964-01-30
IdentifiersMRN HR-ET002-SYN; SSN (made up) 000-02-5130
Document date2026-11-01
AuthorNathaniel Brooks, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Primary care visit for breathlessness, orthopnea, and leg swelling. Concerns: Breathlessness, poor sleep from orthopnea, and leg swelling are cutting short his workdays; Wants to stop smoking without losing his edge at work. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route2026-03-27 to 2026-04-10completedS
Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route2026-04-10activeS
Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route2026-03-27 to 2026-04-10completedS
Carvedilol 6.25 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route2026-04-10 to 2026-06-26completedS
Carvedilol 12.5 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route2026-06-26activeS
Spironolactone 25 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-04-10activeS
Empagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-27activeS
Furosemide 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-27 to 2026-06-26completedS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-27activeS
Nicotine 21 mg/24 hr transdermal patch, apply one patch dailyApply one patch to the skin dailyTopical route2026-03-27 to 2026-06-26completedS
Ferric carboxymaltose 750 mg in 15 mL intravenous infusion, two doses one week apart750 mg intravenously, two doses one week apartIntravenous route2026-04-10 to 2026-04-17completedS

Procedures

ProcedureDatesStatusEvidence
Transthoracic echocardiography2026-04-10 to 2026-04-10completedS
Transthoracic echocardiography2026-09-25 to 2026-09-25completedS

Immunizations

DateVaccineStatusEvidence
2025-10-14Influenza vaccine, 2025-2026 seasoncompletedS
2026-04-10Pneumococcal conjugate vaccine PCV20completedS
2021-05-03Tdap vaccinecompletedS
2026-10-23Influenza vaccine, 2026-2027 seasoncompletedS
2026-10-23Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
August 25, 1921Paralytic illness in August 1921, diagnosed at the time as infantile paralysis (polio); paraplegic thereafter, with leg braces from early 1922D (CLM-0003)
Proposed in 2003 about the 1921 illnessGuillain-Barré syndrome proposed retrospectively as the cause of the 1921 paralysis; disputedR (CLM-0004)
May 1941Severe iron deficiency anemia in May 1941, hemoglobin reported at 4.5 g/100 mLD (CLM-0005)

Family History

RelativeConditionAge at deathEvidence
fatherDied in 1900; cause not recorded in the cited sourceD (CLM-0009)
motherDied in September 1941; cause not recorded in the cited sourceD (CLM-0009)

Health Concerns

ConcernStatusEvidence
Breathlessness, poor sleep from orthopnea, and leg swelling are cutting short his workdaysactiveS
Wants to stop smoking without losing his edge at workactiveS

Assessment

Most recent measures: Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 410 on 2026-09-25; Sodium [Moles/volume] in Serum or Plasma 135 on 2026-07-27; Potassium [Moles/volume] in Serum or Plasma 4.9 on 2026-07-27; Creatinine [Mass/volume] in Serum or Plasma 1.42 on 2026-07-27; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 56 on 2026-07-27; Glucose [Mass/volume] in Serum or Plasma 92 on 2026-07-27; Hemoglobin [Mass/volume] in Blood 13.6 on 2026-06-26; Ferritin [Mass/volume] in Serum or Plasma 236 on 2026-06-26; Iron saturation [Mass Fraction] in Serum or Plasma 27 on 2026-06-26; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 2026-03-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 68 on 2026-09-25; Hemoglobin A1c/Hemoglobin.total in Blood 5.9 on 2026-03-27; Albumin/Creatinine [Mass Ratio] in Urine 22 on 2026-09-25; Overall summary score [KCCQ-12] 78 on 2026-09-25; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-23; Left ventricular Ejection fraction 45 on 2026-09-25; Total score [AUDIT-C] 2 on 2026-10-23 [S]

Strengths and supports: Supports: spouse, an adult daughter who encouraged this visit, and close staff [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1944 findingsactiveconfirmed I11.0S — Synthetic active diagnosis for the teaching episode; the 1944 findings remain D.
Heart failure with reduced ejection fraction, NYHA class III at diagnosisactiveconfirmed I50.22S — Synthetic diagnosis confirmed by echocardiogram in the modern episode.
Nicotine dependence, cigarettesactiveconfirmed F17.210S — Synthetic modern diagnosis linked to documented cigarette smoking.
Iron deficiency anemia in heart failure, repleted with intravenous ironresolvedconfirmed D50.9S — Synthetic finding that echoes the documented 1941 anemia; the modern values are S.
Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputedactiveprovisional B91S — Synthetic modern coding of the documented diagnosis; the alternative cause remains R.
Prediabetesactiveconfirmed R73.03S — Synthetic finding from the baseline HbA1c.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.
Acute viral gastroenteritis with mild volume depletion, resolved with oral rehydration and a short hold of heart failure medicinesresolvedconfirmed A08.4S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-27Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma2850pg/mL<=125 pg/mLHighS
2026-03-27Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-03-27Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-03-27Creatinine [Mass/volume] in Serum or Plasma1.18mg/dL0.74-1.35 mg/dLNormalS
2026-03-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M70mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-27Glucose [Mass/volume] in Serum or Plasma104mg/dL70-99 mg/dLHighS
2026-03-27Hemoglobin [Mass/volume] in Blood12.6g/dL13.2-16.6 g/dLLowS
2026-03-27Ferritin [Mass/volume] in Serum or Plasma48ng/mL30-400 ng/mLNormalS
2026-03-27Iron saturation [Mass Fraction] in Serum or Plasma16%20-50%LowS
2026-03-27Thyrotropin [Units/volume] in Serum or Plasma2.1m[IU]/L0.45-4.5 mIU/LNormalS
2026-03-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation132mg/dL<=99 mg/dLHighS
2026-03-27Hemoglobin A1c/Hemoglobin.total in Blood5.9%<=5.6%HighS
2026-03-27Albumin/Creatinine [Mass Ratio] in Urine64mg/g<=30 mg/gHighS
2026-03-27Overall summary score [KCCQ-12]38{score}S
2026-03-27Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-04-10Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
2026-04-10Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-04-10Creatinine [Mass/volume] in Serum or Plasma1.29mg/dL0.74-1.35 mg/dLNormalS
2026-04-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M63mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-10Glucose [Mass/volume] in Serum or Plasma98mg/dL70-99 mg/dLNormalS
2026-04-10Left ventricular Ejection fraction30%50-70%LowS
2026-06-26Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma980pg/mL<=125 pg/mLHighS
2026-06-26Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-06-26Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-06-26Creatinine [Mass/volume] in Serum or Plasma1.24mg/dL0.74-1.35 mg/dLNormalS
2026-06-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M66mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-06-26Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
2026-06-26Hemoglobin [Mass/volume] in Blood13.6g/dL13.2-16.6 g/dLNormalS
2026-06-26Ferritin [Mass/volume] in Serum or Plasma236ng/mL30-400 ng/mLNormalS
2026-06-26Iron saturation [Mass Fraction] in Serum or Plasma27%20-50%NormalS
2026-06-26Overall summary score [KCCQ-12]64{score}S
2026-06-26Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-09-25Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma410pg/mL<=125 pg/mLHighS
2026-09-25Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-09-25Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-09-25Creatinine [Mass/volume] in Serum or Plasma1.21mg/dL0.74-1.35 mg/dLNormalS
2026-09-25Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M68mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-09-25Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
2026-09-25Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation68mg/dL<=99 mg/dLNormalS
2026-09-25Albumin/Creatinine [Mass Ratio] in Urine22mg/g<=30 mg/gNormalS
2026-09-25Left ventricular Ejection fraction45%50-70%LowS
2026-09-25Overall summary score [KCCQ-12]78{score}S
2026-07-27Sodium [Moles/volume] in Serum or Plasma135mmol/L135-145 mmol/LNormalS
2026-07-27Potassium [Moles/volume] in Serum or Plasma4.9mmol/L3.5-5.1 mmol/LNormalS
2026-07-27Creatinine [Mass/volume] in Serum or Plasma1.42mg/dL0.74-1.35 mg/dLHighS
2026-07-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M56mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-07-27Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
2026-10-23Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-10-23Total score [AUDIT-C]2{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-03-27Body height188cmS
2026-03-27Body weight88kgS
2026-03-27Body mass index (BMI) [Ratio]24.9kg/m2S
2026-03-27Systolic blood pressure186mm[Hg]S
2026-03-27Diastolic blood pressure108mm[Hg]S
2026-03-27Heart rate96/minS
2026-03-27Respiratory rate22/minS
2026-03-27Body temperature36.9CelS
2026-03-27Oxygen saturation in Arterial blood by Pulse oximetry93%S
2026-04-10Body height188cmS
2026-04-10Body weight85kgS
2026-04-10Body mass index (BMI) [Ratio]24kg/m2S
2026-04-10Systolic blood pressure148mm[Hg]S
2026-04-10Diastolic blood pressure88mm[Hg]S
2026-04-10Heart rate84/minS
2026-04-10Respiratory rate18/minS
2026-04-10Body temperature36.8CelS
2026-04-10Oxygen saturation in Arterial blood by Pulse oximetry95%S
2026-06-26Body height188cmS
2026-06-26Body weight83kgS
2026-06-26Body mass index (BMI) [Ratio]23.5kg/m2S
2026-06-26Systolic blood pressure128mm[Hg]S
2026-06-26Diastolic blood pressure78mm[Hg]S
2026-06-26Heart rate70/minS
2026-06-26Respiratory rate16/minS
2026-06-26Body temperature36.7CelS
2026-06-26Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-09-25Body height188cmS
2026-09-25Body weight82kgS
2026-09-25Body mass index (BMI) [Ratio]23.2kg/m2S
2026-09-25Systolic blood pressure122mm[Hg]S
2026-09-25Diastolic blood pressure76mm[Hg]S
2026-09-25Heart rate64/minS
2026-09-25Respiratory rate14/minS
2026-09-25Body temperature36.7CelS
2026-09-25Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-07-27Body height188cmS
2026-07-27Body weight80.6kgS
2026-07-27Body mass index (BMI) [Ratio]22.8kg/m2S
2026-07-27Systolic blood pressure102mm[Hg]S
2026-07-27Diastolic blood pressure64mm[Hg]S
2026-07-27Heart rate86/minS
2026-07-27Respiratory rate16/minS
2026-07-27Body temperature37.6CelS
2026-07-27Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-10-23Body height188cmS
2026-10-23Body weight82kgS
2026-10-23Body mass index (BMI) [Ratio]23.2kg/m2S
2026-10-23Systolic blood pressure120mm[Hg]S
2026-10-23Diastolic blood pressure74mm[Hg]S
2026-10-23Heart rate62/minS
2026-10-23Respiratory rate14/minS
2026-10-23Body temperature36.6CelS
2026-10-23Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-03-27Primary care visit for breathlessness, orthopnea, and leg swellingfinishedS
2026-04-10Two-week heart failure medication safety check and echocardiogramfinishedS
2026-06-26Three-month heart failure and blood pressure reviewfinishedS
2026-09-25Six-month heart failure review with repeat echocardiogramfinishedS
2026-07-27Same-day sick visit for vomiting and diarrheafinishedS
2026-10-23Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Start guideline-directed therapy for HFrEF: sacubitril/valsartan, carvedilol, and empagliflozin, with furosemide for congestion; add spironolactone after the two-week potassium checkcompletedGL-HF-2022S
Check a basic metabolic panel one to two weeks after each renin-angiotensin or mineralocorticoid antagonist change, then every three to six months when stablecompletedGL-CMID-2026, GL-HF-2022S
Treat to a blood pressure below 130/80 with home blood pressure and daily weight logs; low-sodium dietcompletedGL-HTN-2025, GL-CMID-2026S
Give intravenous ferric carboxymaltose for iron deficiency with ferritin below 100 ng/mL and transferrin saturation below 20%completedGL-HF-2022S
Tobacco cessation counseling with nicotine replacement and a quit datecompletedGL-TOBACCO-2021S
Cardiology referral to confirm the diagnosis, review the echocardiogram, and guide titrationcompletedGL-HF-2022S
Repeat echocardiogram three to six months after reaching tolerated doses to decide on device therapycompletedGL-HF-2022, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
Lower blood pressure below 130/80 by the six-month review2026-09-25completedBlood pressure 122/76S
Improve the KCCQ-12 overall summary score by at least 20 points by the three-month review2026-06-26completedKCCQ-12 rose from 38 to 64S
Stop smoking by the three-month review2026-06-26completedNo cigarettes since April; nicotine patch course completedS
Reach the highest tolerated doses of guideline-directed therapy by the six-month review2026-09-25completedSacubitril/valsartan 49/51 mg twice daily, carvedilol 12.5 mg twice daily, spironolactone, and empagliflozinS

Functional Status

Mental Status